A pilot phase 2 clinical trial is testing the feasibility of the targeted drug palbociclib combined with endocrine therapy as adjuvant therapy for stage II and III breast cancer. The research was reported at the annual meeting of the American Society of Clinical Oncology (ASCO).
At Dana-Farber/Brigham and Women's Cancer Center, we take a team approach to patient care. This means you benefit from the expertise and experience of a team that includes medical, surgical, and radiation oncologists; imaging specialists; pathologists; physicians assistants; nurses and social workers. This group works together to develop and deliver the best treatment plan for you. At Dana-Farber/Brigham and Women's Cancer Center, you are not alone. You have a team with you every step of the way. You have us.
"I'm alive today because of the treatment I've gotten at Dana-Farber," says patient Maura Perkins. View this compelling video of how the unique Susan F. Smith Center for Women's Cancers is helping Maura battle back against ovarian cancer.
Brian Park talks about being a Volunteer at Dana-Farber Cancer Institute in this segment of "Faces of Dana-Farber." The series highlights volunteers and employees that help our patients and their families. Part 1 of 3 for Brian Park.
Andrew Norden, MD talks about the experienced team dedicated to treating brain tumor patients at Dana-Farber Cancer Institute. Here, patients have the opportunity to participate in clinical trials, which expands the options available for brain tumor treatment. Learn more about the approach to care and the clinical trial options available to patients at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Ce...